FDA OKs Novartis' leukemia med Rydapt

|About: Novartis AG (NVS)|By:, SA News Editor

The FDA approves Novartis' (NVS -0.4%) Rydapt (midostaurin), in combination with chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (ALL) who have a genetic mutation called FLT3.

The agency reviewed the application under Priority Review status.

Previously: Novartis' NDA for PKC412 granted Priority Review in U.S. for AML and mastocytosis (Nov. 14, 2016)